The Patent Finder

Agennix Incorporated

Also on record
Records under this name other than patents Agennix Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Agennix Incorporated

PatentTitleStatus Expires Confidence
US 6,080,559Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
Term ended
Term ended Jun 29, 2018 · From the USPTO record
Term endedTerm ended Jun 29, 2018From the USPTO record
US 7,026,295Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
Lapsed on the fee record
Ended Apr 11, 2018 · From the USPTO record
Lapsed on the fee recordEnded Apr 11, 2018From the USPTO record
US 7,638,487Lactoferrin in the reduction of pain
Lapsed on the fee record
Ended Dec 29, 2017 · From the USPTO record
Lapsed on the fee recordEnded Dec 29, 2017From the USPTO record
US 7,592,306Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
Lapsed on the fee record
Ended Sep 22, 2017 · From the USPTO record
Lapsed on the fee recordEnded Sep 22, 2017From the USPTO record
US 6,111,081Lactoferrin variants and uses thereof
Formerly held
Term ended
Term ended May 30, 2017 · From the USPTO record
Term endedTerm ended May 30, 2017From the USPTO record
US 7,524,814Lactoferrin compositions and methods of wound treatment
Lapsed on the fee record
Ended Apr 28, 2017 · From the USPTO record
Lapsed on the fee recordEnded Apr 28, 2017From the USPTO record
US 7,420,033Composition of lactoferrin related peptides and uses thereof
Lapsed on the fee record
Ended Sep 2, 2016 · From the USPTO record
Lapsed on the fee recordEnded Sep 2, 2016From the USPTO record
US 8,247,373Lactoferrin compositions and methods of wound treatment
Lapsed on the fee record
Ended Aug 21, 2016 · From the USPTO record
Lapsed on the fee recordEnded Aug 21, 2016From the USPTO record
US 8,242,079Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
Lapsed on the fee record
Ended Aug 14, 2016 · From the USPTO record
Lapsed on the fee recordEnded Aug 14, 2016From the USPTO record
US 8,105,615Lactoferrin as an adjuvant in cancer vaccines
Lapsed on the fee record
Ended Jan 31, 2016 · From the USPTO record
Lapsed on the fee recordEnded Jan 31, 2016From the USPTO record
10 of 33 patents shown.
Pro members see all 33.
Pro members: see all 33 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited